AQW051   Click here for help

GtoPdb Ligand ID: 7371

Synonyms: AQW-051 | VQW 765 | VQW-765 | VQW765
Compound class: Synthetic organic
Comment: AQW 051 is an α7 nicotinic acetylcholine receptor (nAChR) partial agonist from Novartis for the oral treatment of cognitive deficits in schizophrenia, Alzheimer's, and Parkinson's diseases [1,3]. Structure first disclosed at March 2014 ACS meeting. The (3S) version is CID 71553840. The compound was later re-named to VQW-765 (Vanda Pharmaceuticals).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 0
Rotatable bonds 3
Topological polar surface area 25.36
Molecular weight 294.17
XLogP 3.57
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES Cc1ccc(cc1)c1ccc(cn1)OC1CN2CCC1CC2
Isomeric SMILES Cc1ccc(cc1)c1ccc(cn1)O[C@H]1CN2CCC1CC2
InChI InChI=1S/C19H22N2O/c1-14-2-4-15(5-3-14)18-7-6-17(12-20-18)22-19-13-21-10-8-16(19)9-11-21/h2-7,12,16,19H,8-11,13H2,1H3/t19-/m0/s1
No information available.
Summary of Clinical Use Click here for help
Trials have been registered for schizophrenia, Alzheimer's, and Parkinson's diseases in entries. Note that the Alzheimer's 2009 trial was terminated. The asset has now been repositioned by Vanda Pharmaceuticals for potential to ameliorate social/performance anxiety.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04800237 Evaluating the Effects of VQW-765 vs. Placebo in Performance Anxiety Phase 2 Interventional Vanda Pharmaceuticals
NCT01474421 Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease Phase 2 Interventional Novartis 5